Edivoxetine (INN; LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly as an antidepressant and as a treatment for attention-deficit hyperactivity disorder (ADHD). As of 2012 it is in phase III clinical trials for major depressive disorder with initial approval expected by 2013.
This page contains content from the copyrighted Wikipedia article "Edivoxetine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
